cancer diagnostics
- Home
- cancer diagnostics
Public
Opening a new frontier in treating Parkinson’s disease
- Review
- November 11, 2022
Is this the most hated company on the ASX?
- Review
- August 16, 2019
Latest Articles
CLEO meets with US FDA to develop strategy for ovarian cancer test launch
Ovarian cancer diagnostics company Cleo Diagnostics (ASX: COV) has taken a major step towards the US launch of its pre-surgical triage test for ovarian cancer detection. The Company wrapped up an initial pre-submission meeting with the U.S. Food and Drug Administration (FDA), thus setting its regulatory journey in motion. Ovarian cancer is a serious health
Read MorePublic
Rhythm Biosciences nears commercialisation of revolutionary cancer test following filing of approval documents with the TGA
Rhythm Biosciences (ASX: RHY) is a step closer to commercialising their bowel cancer detection test, having submitted documents to the Australian Therapeutic Goods Administration (TGA) for approval. The filing is a significant milestone for the Company who are hoping to launch their product to market later this year. Rhythm’s test offers a convenient and non-invasive
Read MorePublic
Theranos, but make it legit.. Does this company have the answer to cancer detection via blood test?
Treating cancer is a primary goal of many biotech companies, but for any treatment to begin, physicians need a definitive diagnosis. We know that time is critical in disease diagnosis and initiating treatment sooner translates to better patient outcomes more often than not. The field of diagnostics is the yin to medical treatment’s yang. They
Read MorePublic
Universal Biosensors partners with Peter Mac for handheld cancer diagnosis device
A handheld device which can remotely diagnose the presence of cancer cells is on the horizon with biotech company Universal Biosensors (ASX: UBI) partnering with the Peter MacCallum Cancer Centre on the project. Under the agreement, Peter Mac will supply cancer patient samples to Universal Biosensors which will use the plasma samples in their trials
Read MorePublic
How BCAL Diagnostics is improving minimally invasive methods of early cancer detection
With 1 in 7 Australian women diagnosed with breast cancer, the demand for a minimally invasive, accurate diagnostic test is growing. Whilst health professionals recommend bi-annual breast screening for women aged 50-74, the invasive nature of imaging and ultrasound techniques leads to low compliance. There is well documented evidence that early cancer detection markedly improves
Read MorePublic
Truscreen expands market for real time digital diagnostic testing device
Ahh the pap smear. The daunting, uncomfortable and downright annoying process of having a cervical swab taken to be tested for cancerous or precancerous cells, only to be repeated in 3-5 years time. Despite being an important aspect of women’s health – COVID-19, uncomfortable gyno appointments, and misinformation means that booking in for that test
Read MorePublic
- 1
- 2
